<p>以色列拉马特甘，2025 年 12 月 24 日（全球新闻稿）——XTL 生物制药有限公司（Nasdaq:XTLB）（TASE:XTLB.TA）（以下简称 “公司” 或 “XTL”）今天宣布，已收到纳斯达克证券市场有限责任公司（“纳斯达克”）上市资格部门于 2025 年 12 月 22 日发出的通知函，通知公司根据 XTL 在过去 30 个连续交易日的收盘报价，目前未能满足纳斯达克持续上市要求，即每股最低报价为 1 美元的要求。</p>
<p>纳斯达克的通知函并不会导致公司美国存托股票（“ADSs”）的立即退市，ADSs 将继续在 “XTLB” 符号下不间断交易。</p>
<p>根据纳斯达克上市规则 5810(c)(3)(A)，公司有 180 个日历天的合规期，直到 2026 年 6 月 22 日，以恢复合规。如果在这 180 天期间内，公司证券的收盘报价至少为 1 美元，且持续十个交易日，纳斯达克将向 XTL 提供书面合规确认，此事将结束。</p>
<p>如果公司未能恢复合规，XTL 可能有资格获得额外的时间。为符合资格，公司需要满足公开持股的市场价值和纳斯达克资本市场的所有其他初始上市标准，除了报价要求，并需要在第二个合规期内提供书面通知，表明其打算通过必要时进行反向股票拆分来弥补缺陷。如果 XTL 满足这些要求，纳斯达克将通知公司已获得额外的 180 个日历天。然而，如果纳斯达克认为公司无法弥补缺陷，或公司其他方面不符合资格，纳斯达克将发出通知，表明其证券将面临退市。</p>
<p>XTL 目前正在评估恢复合规的选项，并打算及时恢复符合纳斯达克的持续上市要求。尽管 XTL 将尽一切合理努力以达到规则 5550(a)(2) 的合规要求，但不能保证公司能够恢复对该规则的合规，或在其他纳斯达克持续上市要求方面保持合规。</p>
<p><strong>关于 XTL 生物制药有限公司</strong></p>
<p>XTL 是一家知识产权组合公司。XTL 持有 The Social Proxy Ltd.（“Social Proxy”）100% 的股本，该公司是一家网络数据公司，并已就 hCDR1 的知识产权组合进行再许可，以治疗狼疮疾病。Social Proxy 是一家网络数据人工智能公司，开发并提供一个独特的伦理、基于知识产权的代理数据提取平台，用于大规模的人工智能和商业智能应用。</p>
<p><strong>关于前瞻性声明的警示说明</strong></p>
<p>本通讯包含根据 1933 年证券法第 27A 条及 1934 年证券交易法第 21E 条的定义的前瞻性声明。本通讯中包含的任何非历史事实的陈述可能被视为前瞻性声明。诸如 “继续”、“将”、“可能”、“应该”、“期望”、“预计”、“计划”、“打算”、“预期”、“相信”、“估计”、“预测”、“潜在” 等类似词汇旨在识别此类前瞻性声明。所有前瞻性声明都涉及重大风险和不确定性，可能导致实际结果与前瞻性声明中表达或暗示的结果有实质性差异，其中许多通常超出公司的控制范围，且难以预测。这些风险和不确定性的例子包括但不限于（i）公司是否能够收到与其 Hcdr1 知识产权相关的再许可费用，（ii）公司成功管理和整合 Social Proxy 及任何其他合资企业、业务收购、解决方案或技术的能力；（iii）意外的运营成本、交易成本及实际或或有负债；（iv）吸引和留住合格员工及关键人员的能力；（v）竞争加剧对公司未来业务的不利影响；（vi）公司保护其知识产权的能力；以及（vii）地方、行业及一般商业和经济条件。可能导致实际结果与前瞻性声明中表达或暗示的结果有实质性差异的其他因素可以在公司向证券交易委员会提交的最新 20-F 表格年度报告和 6-K 表格当前报告中找到。公司预计后续事件和发展可能导致其计划、意图和预期发生变化。公司不承担任何义务，并明确声明不打算或不承担更新任何前瞻性声明的责任，无论是由于新信息、未来事件还是其他原因，除非法律明确要求。前瞻性声明仅在作出之日有效，不应被视为公司在任何后续日期的计划和预期的代表。</p>
<p><strong>如需更多信息，请联系：</strong></p>
<p>投资者关系，XTL 生物制药有限公司。</p>
<p>电话：+972 3 611 6666</p>
<p>电子邮件：info@xtlbio.com</p>
<p>www.xtlbio.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE56QXhOeU0zTXpNMU9UWTJJelV3TURBMk5qUTNPQT09?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE56QXhOeU0zTXpNMU9UWTJJelV3TURBMk5qUTNPQT09"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YTczMzMwMjgtNzQ0MC00MmRjLTk0NzktYWFjMTQ0MDg4NGQ4LTUwMDA2NjQ3OC0yMDI1LTEyLTI0LWVu/tiny/XTL-Biopharmaceuticals-Ltd-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YTczMzMwMjgtNzQ0MC00MmRjLTk0NzktYWFjMTQ0MDg4NGQ4LTUwMDA2NjQ3OC0yMDI1LTEyLTI0LWVu/tiny/XTL-Biopharmaceuticals-Ltd-.png"/></p>

XTL生物制药

<p>XTL 生物制药有限公司收到了纳斯达克的通知，因未满足每股最低出价要求 1 美元。该公司有 180 天的时间来恢复合规，可能通过反向股票拆分来实现。XTL 的股票将继续以 “XTLB” 进行交易。如果未能实现合规，若满足其他上市标准，XTL 可能会获得额外的时间。该公司正在探索解决这一缺陷的选项</p>

<p>RAMAT GAN, ISRAEL, Dec. 24, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “ <strong>Company</strong>” or “ <strong>XTL</strong>”), announced today that it has received a notification letter from The Listing Qualifications Department of The Nasdaq Stock Market LLC (“ <strong>Nasdaq</strong>”), dated December 22, 2025, notifying the Company that based on XTL’s closing bid price for the last 30 consecutive business days, the Company currently does not meet the continued listing requirement of Nasdaq, under Nasdaq Listing Rules 5550(a)(2), to maintain a minimum bid price of $1 per share.</p>
<div class="lb-trans"><p>以色列拉马特甘，2025 年 12 月 24 日（全球新闻稿）——XTL 生物制药有限公司（Nasdaq:XTLB）（TASE:XTLB.TA）（以下简称 “公司” 或 “XTL”）今天宣布，已收到纳斯达克证券市场有限责任公司（“纳斯达克”）上市资格部门于 2025 年 12 月 22 日发出的通知函，通知公司根据 XTL 在过去 30 个连续交易日的收盘报价，目前未能满足纳斯达克持续上市要求，即每股最低报价为 1 美元的要求。</p>
</div><p>The Nasdaq notification letter does not result in the immediate delisting of the Company’s American Depositary Shares (“ <strong>ADSs</strong>”), and the ADSs will continue to trade uninterrupted under the symbol “XTLB”.</p>
<div class="lb-trans"><p>纳斯达克的通知函并不会导致公司美国存托股票（“ADSs”）的立即退市，ADSs 将继续在 “XTLB” 符号下不间断交易。</p>
</div><p>Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until June 22, 2026, to regain compliance. If at any time during this 180-day period the closing bid price of the Company’s security is at least $1 for a minimum of ten consecutive business days, Nasdaq will provide XTL with written confirmation of compliance and this matter will be closed.</p>
<div class="lb-trans"><p>根据纳斯达克上市规则 5810(c)(3)(A)，公司有 180 个日历天的合规期，直到 2026 年 6 月 22 日，以恢复合规。如果在这 180 天期间内，公司证券的收盘报价至少为 1 美元，且持续十个交易日，纳斯达克将向 XTL 提供书面合规确认，此事将结束。</p>
</div><p>In the event the Company does not regain compliance, XTL may be eligible for additional time. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If XTL meets these requirements, Nasdaq will inform the Company that it has been granted an additional 180 calendar days. However, if it appears to Nasdaq that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will provide notice that its securities will be subject to delisting.</p>
<div class="lb-trans"><p>如果公司未能恢复合规，XTL 可能有资格获得额外的时间。为符合资格，公司需要满足公开持股的市场价值和纳斯达克资本市场的所有其他初始上市标准，除了报价要求，并需要在第二个合规期内提供书面通知，表明其打算通过必要时进行反向股票拆分来弥补缺陷。如果 XTL 满足这些要求，纳斯达克将通知公司已获得额外的 180 个日历天。然而，如果纳斯达克认为公司无法弥补缺陷，或公司其他方面不符合资格，纳斯达克将发出通知，表明其证券将面临退市。</p>
</div><p>XTL is currently evaluating options to regain compliance and intends to timely regain compliance with Nasdaq’s continued listing requirements. Although XTL will use all reasonable efforts to achieve compliance with Rule 5550(a)(2), there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq continued listing requirements.</p>
<div class="lb-trans"><p>XTL 目前正在评估恢复合规的选项，并打算及时恢复符合纳斯达克的持续上市要求。尽管 XTL 将尽一切合理努力以达到规则 5550(a)(2) 的合规要求，但不能保证公司能够恢复对该规则的合规，或在其他纳斯达克持续上市要求方面保持合规。</p>
</div><p><strong>About XTL Biopharmaceuticals Ltd.</strong></p>
<div class="lb-trans"><p><strong>关于 XTL 生物制药有限公司</strong></p>
</div><p>XTL is an IP portfolio company. XTL holds 100% of the share capital of The Social Proxy Ltd. (the “Social Proxy”), a web data company, and has sublicensed out an IP portfolio surrounding hCDR1 for the treatment of Lupus disease. The Social Proxy is a web data AI company, developing and powering a unique ethical, IP based, proxy data extraction platform for AI and BI applications at scale.</p>
<div class="lb-trans"><p>XTL 是一家知识产权组合公司。XTL 持有 The Social Proxy Ltd.（“Social Proxy”）100% 的股本，该公司是一家网络数据公司，并已就 hCDR1 的知识产权组合进行再许可，以治疗狼疮疾病。Social Proxy 是一家网络数据人工智能公司，开发并提供一个独特的伦理、基于知识产权的代理数据提取平台，用于大规模的人工智能和商业智能应用。</p>
</div><p><strong>Cautionary Note Regarding Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>关于前瞻性声明的警示说明</strong></p>
</div><p>This communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained in this communication that are not statements of historical fact may be deemed forward-looking statements. Words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of the Company and are difficult to predict. Examples of such risks and uncertainties include, but are not limited to (i) whether to the Company will be able to receive sub-licensing fees relating to its Hcdr1 intellectual property, (ii) the Company’s ability to successfully manage and integrate The Social Proxy and any other joint ventures, acquisitions of businesses, solutions or technologies; (iii) unanticipated operating costs, transaction costs and actual or contingent liabilities; (iv) the ability to attract and retain qualified employees and key personnel; (v) adverse effects of increased competition on the Company’s future business; (vi) the Company’s ability to protect its intellectual property; and (vii) local, industry and general business and economic conditions. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 20-F and current reports on Form 6-K filed by the Company with the Securities and Exchange Commission. The Company anticipates that subsequent events and developments may cause its plans, intentions and expectations to change. The Company assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law. Forward-looking statements speak only as of the date they are made and should not be relied upon as representing the Company’s plans and expectations as of any subsequent date.</p>
<div class="lb-trans"><p>本通讯包含根据 1933 年证券法第 27A 条及 1934 年证券交易法第 21E 条的定义的前瞻性声明。本通讯中包含的任何非历史事实的陈述可能被视为前瞻性声明。诸如 “继续”、“将”、“可能”、“应该”、“期望”、“预计”、“计划”、“打算”、“预期”、“相信”、“估计”、“预测”、“潜在” 等类似词汇旨在识别此类前瞻性声明。所有前瞻性声明都涉及重大风险和不确定性，可能导致实际结果与前瞻性声明中表达或暗示的结果有实质性差异，其中许多通常超出公司的控制范围，且难以预测。这些风险和不确定性的例子包括但不限于（i）公司是否能够收到与其 Hcdr1 知识产权相关的再许可费用，（ii）公司成功管理和整合 Social Proxy 及任何其他合资企业、业务收购、解决方案或技术的能力；（iii）意外的运营成本、交易成本及实际或或有负债；（iv）吸引和留住合格员工及关键人员的能力；（v）竞争加剧对公司未来业务的不利影响；（vi）公司保护其知识产权的能力；以及（vii）地方、行业及一般商业和经济条件。可能导致实际结果与前瞻性声明中表达或暗示的结果有实质性差异的其他因素可以在公司向证券交易委员会提交的最新 20-F 表格年度报告和 6-K 表格当前报告中找到。公司预计后续事件和发展可能导致其计划、意图和预期发生变化。公司不承担任何义务，并明确声明不打算或不承担更新任何前瞻性声明的责任，无论是由于新信息、未来事件还是其他原因，除非法律明确要求。前瞻性声明仅在作出之日有效，不应被视为公司在任何后续日期的计划和预期的代表。</p>
</div><p><strong>For further information, please contact:</strong></p>
<div class="lb-trans"><p><strong>如需更多信息，请联系：</strong></p>
</div><p>Investor Relations, XTL Biopharmaceuticals Ltd.</p>
<div class="lb-trans"><p>投资者关系，XTL 生物制药有限公司。</p>
</div><p>Tel: +972 3 611 6666</p>
<div class="lb-trans"><p>电话：+972 3 611 6666</p>
</div><p>Email: info@xtlbio.com</p>
<div class="lb-trans"><p>电子邮件：info@xtlbio.com</p>
</div><p>www.xtlbio.com</p>
<div class="lb-trans"><p>www.xtlbio.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE56QXhOeU0zTXpNMU9UWTJJelV3TURBMk5qUTNPQT09" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYxNzAxNyM3MzM1OTY2IzUwMDA2NjQ3OA=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YTczMzMwMjgtNzQ0MC00MmRjLTk0NzktYWFjMTQ0MDg4NGQ4LTUwMDA2NjQ3OC0yMDI1LTEyLTI0LWVu/tiny/XTL-Biopharmaceuticals-Ltd-.png" alt="" original-src="https://ml.globenewswire.com/media/YTczMzMwMjgtNzQ0MC00MmRjLTk0NzktYWFjMTQ0MDg4NGQ4LTUwMDA2NjQ3OC0yMDI1LTEyLTI0LWVu/tiny/XTL-Biopharmaceuticals-Ltd-.png"/></p>

XTL 宣布收到纳斯达克关于最低出价价格不足的通知信 | XTLB 股票新闻